Article Information
History
- December 13, 2020.
Article Versions
- You are currently viewing Version 1 of this article (December 13, 2020 - 20:01).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Paolo Bosetti1,
- Cécile Tran Kiem1,2,
- Yazdan Yazdanpanah3,
- Arnaud Fontanet4,5,
- Bruno Lina6,7,
- Vittoria Colizza8 and
- Simon Cauchemez1,*
- 1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
- 2Collège Doctoral, Sorbonne Université, Paris, France
- 3Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France
- 4Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France
- 5PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France
- 6National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France
- 7Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS—UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France
- 8INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris 75012, France
- ↵*Corresponding author:
Simon Cauchemez, Corresponding author email:
simon.cauchemez{at}pasteur.fr
Posted December 13, 2020.
Impact of mass testing during an epidemic rebound of SARS-CoV-2: A modelling study
